Shanxi Zhendong Pharmaceutical (300158) - Total Assets
Based on the latest financial reports, Shanxi Zhendong Pharmaceutical (300158) holds total assets worth CN¥4.51 Billion CNY (≈ $660.15 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 300158 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Shanxi Zhendong Pharmaceutical - Total Assets Trend (2007–2024)
This chart illustrates how Shanxi Zhendong Pharmaceutical's total assets have evolved over time, based on quarterly financial data. Explore Shanxi Zhendong Pharmaceutical long-term investment allocation to see how much of total assets are deployed in long-term investments.
Shanxi Zhendong Pharmaceutical - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanxi Zhendong Pharmaceutical's total assets of CN¥4.51 Billion consist of 64.5% current assets and 35.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.7% |
| Accounts Receivable | CN¥775.81 Million | 15.6% |
| Inventory | CN¥775.98 Million | 15.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥371.90 Million | 7.5% |
| Goodwill | CN¥15.50 Million | 0.3% |
Asset Composition Trend (2007–2024)
This chart illustrates how Shanxi Zhendong Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300158 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanxi Zhendong Pharmaceutical's current assets represent 64.5% of total assets in 2024, an increase from 46.0% in 2007.
- Cash Position: Cash and equivalents constituted 11.7% of total assets in 2024, up from 7.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, a decrease from 15.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 15.6% of total assets.
Shanxi Zhendong Pharmaceutical Competitors by Total Assets
Key competitors of Shanxi Zhendong Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Shanxi Zhendong Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.14 | 5.40 | 2.24 |
| Quick Ratio | 2.35 | 3.91 | 1.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.80 Billion | CN¥3.22 Billion | CN¥2.11 Billion |
Shanxi Zhendong Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Shanxi Zhendong Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.74 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | -19.4% |
| Total Assets | CN¥4.98 Billion |
| Market Capitalization | $698.44 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanxi Zhendong Pharmaceutical's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shanxi Zhendong Pharmaceutical's assets decreased by 19.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanxi Zhendong Pharmaceutical (2007–2024)
The table below shows the annual total assets of Shanxi Zhendong Pharmaceutical from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.98 Billion ≈ $729.13 Million |
-19.38% |
| 2023-12-31 | CN¥6.18 Billion ≈ $904.40 Million |
-5.65% |
| 2022-12-31 | CN¥6.55 Billion ≈ $958.60 Million |
-35.10% |
| 2021-12-31 | CN¥10.09 Billion ≈ $1.48 Billion |
+32.75% |
| 2020-12-31 | CN¥7.60 Billion ≈ $1.11 Billion |
+9.95% |
| 2019-12-31 | CN¥6.92 Billion ≈ $1.01 Billion |
-4.12% |
| 2018-12-31 | CN¥7.21 Billion ≈ $1.06 Billion |
-5.27% |
| 2017-12-31 | CN¥7.61 Billion ≈ $1.11 Billion |
+10.75% |
| 2016-12-31 | CN¥6.87 Billion ≈ $1.01 Billion |
+68.89% |
| 2015-12-31 | CN¥4.07 Billion ≈ $595.64 Million |
+42.41% |
| 2014-12-31 | CN¥2.86 Billion ≈ $418.26 Million |
+2.20% |
| 2013-12-31 | CN¥2.80 Billion ≈ $409.27 Million |
+8.25% |
| 2012-12-31 | CN¥2.58 Billion ≈ $378.09 Million |
+14.54% |
| 2011-12-31 | CN¥2.26 Billion ≈ $330.10 Million |
+3.93% |
| 2010-12-31 | CN¥2.17 Billion ≈ $317.61 Million |
+237.46% |
| 2009-12-31 | CN¥643.18 Million ≈ $94.12 Million |
+29.49% |
| 2008-12-31 | CN¥496.69 Million ≈ $72.68 Million |
+6.43% |
| 2007-12-31 | CN¥466.70 Million ≈ $68.29 Million |
-- |
About Shanxi Zhendong Pharmaceutical
Shanxi Zhendong Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sales of pharmaceutical drugs in China. It offers drugs for various fields, including tumors, dermatology, digestion, urology, and cardio-cerebral drugs. The company also provides Chinese herbal medicines. Shanxi Zhendong Pharmaceutical Co.,Ltd was founded in 1995 and is b… Read more